NCT06176365 (SYNCHRONIZE™JP) is a Phase 3 clinical trial of Survodutide in Obesity, sponsored by Boehringer Ingelheim.

Who is sponsoring NCT06176365?

NCT06176365 is sponsored by Boehringer Ingelheim.

What drugs are being tested in NCT06176365?

Interventions in NCT06176365: Survodutide, Placebo matching survodutide.

Is NCT06176365 still recruiting?

NCT06176365 is currently completed. Last updated 12 December 2025.

Last reviewed 2025-12-12 · How we verify

NCT06176365: SYNCHRONIZE™JP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease

Completed Phase 3 Last updated 12 December 2025

What this trial tests

Phase 3 trial testing Survodutide in Obesity in 274 participants. Completed in 3 December 2025.

Timeline

16 January 2024

Primary endpoint
3 December 2025

3 December 2025

Quick facts

Lead sponsor	Boehringer Ingelheim
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	274
Start date	16 January 2024
Primary completion	3 December 2025
Estimated completion	3 December 2025
Sites	28 locations across Japan

Drugs / interventions tested

Survodutide — full drug profile →
Placebo matching survodutide — full drug profile →

Conditions studied

Obesity — all drugs for Obesity →

Sponsor

Boehringer Ingelheim — full company profile →

Who can join

18 and older, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is open to adults who are at least 18 years old and have * a body mass index (BMI) of 35 kg/m² or more and at least one health problem related to their weight, or * a BMI of 27 kg/m² or more and at least two health problems related to their weight. People who have either type 2 diabetes, high blood pressure, or increased blood lipids can take part in this study. Only people who have previously not managed to lose weight by changing their diet can participate. The purpose of this study is to find out whether a medicine called survodutide (BI 456906) helps people living with obesity disease to lose weight. Participants are divided into 3 groups by chance, like drawing names from a hat. 2 groups get different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Every participant has a 2 in 3 chance of getting survodutide. Participants inject survodutide or placebo under their skin once a week for about one and a half years. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly. Participants are in the study for about 1 year and 7 months. During this time, it is planned that participants visit the study site up to 14 times and receive 6 phone calls by the site staff. The doctors check participants' health and take note of any unwanted effects. The participants' body weight is regularly measured. The results are compared between the groups to see whether the treatment works.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024.
Tamargo J, Agewall S, Ambrosio G, Borghi C, et al · · 2025 · cited 6× · PMID 40058879 · DOI 10.1093/ehjcvp/pvaf012
An Overview of Existing and Emerging Weight-Loss Drugs to Target Obesity-Related Complications: Insights from Clinical Trials.
Kim MK, Kim HS. · · 2025 · cited 4× · PMID 39696983 · DOI 10.4062/biomolther.2024.228
Review: Special Issue: <i>Real-world evidence on the use of GLP1 receptor agonists</i>: Emerging concepts in obesity management: focus on glucagon receptor agonist combinations.
Anderson SL. · · 2025 · cited 2× · PMID 40734920 · DOI 10.7573/dic.2025-4-8
Current Trends and Perspectives on Obesity and Metabolic Dysfunction-Associated Steatohepatitis in East Asia.
Lim S, Zhou H, Ogawa W. · · 2026 · cited 1× · PMID 41771545 · DOI 10.7570/jomes25083
Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial.
Yokote K, Yamauchi T, Fukushima Y, Takatsuka Y, et al · · 2026 · PMID 42219222 · DOI 10.1111/dom.70862

Verify or expand the search:

Other trials of Survodutide

Trials testing the same drug.

NCT06745284 — A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity · Phase 1 · active not recruiting
NCT06632457 — LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have C · Phase 3 · recruiting
NCT06564441 — A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood · Phase 1 · completed
NCT06632444 — LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or A · Phase 3 · recruiting
NCT06309992 — A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Live · Phase 3 · completed

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other Boehringer Ingelheim trials

Trials by the same sponsor.

NCT07044700 — Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection · not yet recruiting
NCT07047508 — Real-world Study to Describe the Effectiveness and Safety Outcomes of Jardiance in Chinese Patients With Heart Failure a · not yet recruiting
NCT07366034 — A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With I · Phase 3 · not yet recruiting
NCT07531628 — A Study to Test How Verducatib is Taken up in the Body of Healthy Chinese Participants · Phase 1 · not yet recruiting
NCT07497087 — A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06176365 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Boehringer Ingelheim
Last refreshed: 12 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06176365.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing